The most common indication for lung transplantation in the unmatched cohort of the groups was COPD/Emphysema (EVLP cohort, 19 of 57 (33.3%); non-EVLP cohort, 59 of 202 (29.2%)) followed by alpha-1-antitrypsin deficiency in the non-EVLP arm (non-EVLP arm, 32 of 202 (15.8%); EVLP arm, 3 of 57 (5.3%)) and idiopathic pulmonary fibrosis in the EVLP group (EVLP group, 10 of 57 (17.6%); non-EVLP group, 22 of 202 (10.9%)). This evidence concerns the gene SERPINA1 and pulmonary fibrosis.